IDT Australia Limited (AU:IDT) has released an update.
IDT Australia Limited has reported a 48% surge in third-quarter operating revenue, reaching $3.2 million, and has seen an impressive 27% increase in year-to-date sales compared to the entire previous fiscal year. The growth was driven by significant gains across its three business pillars, particularly a 70% rise in Active Pharmaceutical Ingredients and a 139% increase in Advanced Therapies. The company’s financial outlook remains positive with the recent securing of a substantial contract with Sanofi to develop mRNA-based vaccines.
For further insights into AU:IDT stock, check out TipRanks’ Stock Analysis page.
